DLX6 and hepatocellular carcinoma: Recently, growing reports have indicated that DLX6-AS1 could interact with the target miRNAs to regulate the progression and treatment resistance of multiple cancers, including lung adenocarcinoma (LUAC)12, ovarian cancer13, hepatocellular cancer (HCC)14, glioma15 and bladder cancer16.